This T32 Training Grant has focused successfully over the past 30 years on providing a dynamic research training environment for pathologists, other physician-scientists and basic scientists working in the molecular pathology of cancer. Over the past two 5-year funding periods, trainees have published a considerable number of papers, including in high quality journals, and have found faculty positions in prestigious medical schools. The present proposal features 20 Harvard Medical School and Massachusetts Institute of Technology faculty who are centered in the Massachusetts General Hospital Molecular Pathology Unit and Center for Cancer Research. This interactive, overlapping community of scientists and physician-scientists is organized into thematic programs in cancer genetics;animal models of cancer;mechanisms of gene expression and protein folding;cell cycle control and DNA damage repair;stem cell biology;and in vivo imaging for cancer biology and diagnosis. As in previous cycles, the trainees will be selected from a competitive pool of MD, MD-PhD and PhD applicants on the basis of prior academic and research achievements and evidence of a strong commitment to a career in cancer biology. The period of training will be two or three years for each successful applicant. An active and program-specific recruitment and retention program to enhance diversity ensures that diverse applicants have access to, and succeed in, the training program. In summary, the proposed T32 program renewal capitalizes on a highly interactive, experienced and focused faculty;a distinguished record of training productive physicians and scientists, including underrepresented minorities;state-of-the- art facilities and educational resources;and exposure of the trainees to basic and translational aspects of cancer biology.
Cancer remains a major cause of morbidity and mortality in the United States, and new approaches to the diagnosis and treatment of cancer are therefore necessary. This T32 program focuses on the training of physician-scientists and scientists who plan research careers that will improve our understanding of the molecular basis of human cancers. The program is based on the translational and basic science strengths of a Pathology department and a Cancer Center, and thus creates a dynamic platform to educate physician-scientists and scientists in the study of cancer biology.
|Tian, Feng; Yang, Wenlong; Mordes, Daniel A et al. (2016) Monitoring peripheral nerve degeneration in ALS by label-free stimulated Raman scattering imaging. Nat Commun 7:13283|
|Chavez, Alejandro; Tuttle, Marcelle; Pruitt, Benjamin W et al. (2016) Comparison of Cas9 activators in multiple species. Nat Methods 13:563-7|
|Hill, Sarah J; Mordes, Daniel A; Cameron, Lisa A et al. (2016) Two familial ALS proteins function in prevention/repair of transcription-associated DNA damage. Proc Natl Acad Sci U S A 113:E7701-E7709|
|Masia, Ricard; Krause, Daniela S; Yellen, Gary (2015) The inward rectifier potassium channel Kir2.1 is expressed in mouse neutrophils from bone marrow and liver. Am J Physiol Cell Physiol 308:C264-76|
|Chavez, Alejandro; Scheiman, Jonathan; Vora, Suhani et al. (2015) Highly efficient Cas9-mediated transcriptional programming. Nat Methods 12:326-8|
|Kiani, Samira; Chavez, Alejandro; Tuttle, Marcelle et al. (2015) Cas9 gRNA engineering for genome editing, activation and repression. Nat Methods 12:1051-4|
|Ryan, Russell J H; Drier, Yotam; Whitton, Holly et al. (2015) Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma. Cancer Discov 5:1058-71|
|Khor, Bernard; Gagnon, John D; Goel, Gautam et al. (2015) The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells. Elife 4:|
|Hariri, Lida P; Mino-Kenudson, Mari; Lanuti, Michael et al. (2015) Diagnosing lung carcinomas with optical coherence tomography. Ann Am Thorac Soc 12:193-201|
|Bar-Nur, Ori; Verheul, Cassandra; Sommer, Andreia G et al. (2015) Lineage conversion induced by pluripotency factors involves transient passage through an iPSC stage. Nat Biotechnol 33:761-8|
Showing the most recent 10 out of 113 publications